retatrutide nonalcoholic steatohepatitis nash trial fatty liver disease Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming Top Nonalcoholic Fatty Liver Disease

The American Journal of Sports Medicine, 48 (8), 1916-1928

A new safety signal emerged: dysesthesia (abnormal sense of touch) affected 20.9% of patients on the highest dose, though it was generally mild

You can also typically use them twice daily without an adjustment period, unlike many other active ingredients

Image credit: Tetiana_Kryvous/Shutterstock.com A new study in the Medical Journal of Australia examines the use of glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) in reproductive-age women in Australia to effectively manage type 2 diabetes mellitus, along with contraception overlap and pregnancy incidence in this population

The environmental estrogen bisphenol a inhibits estradiol-induced hippocampal synaptogenesis